Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant’s patents for blockbuster MS drug Gilenya.
The High Court will not wade into the global debate over whether artificial intelligence inventions should receive patent protection, letting stand a Full Court judgment that overturned a landmark victory for AI pioneer Dr Stephen Thaler.
Media company The Economist has failed in its opposition to registration of a trade mark for The Beer Economist, with an IP Australia delegate saying the mark was not substantially identical or deceptively similar to the UK publisher’s brand.
Infant formula maker Care A2 Plus has launched an attack on A2 Milk, filing a lawsuit arguing the dairy giant’s trade marks should be cancelled because they’re too generic and are being used to sell products that don’t exclusively contain the a2 protein.
The maker of Finish dishwashing products has appealed a judgment that removed two of its trade marks for non-use and rejected its claim that a competitor’s logo was deceptively similar.
Swiss pharmaceutical company Biogen and Australian generic drug maker Pharmacor have dropped their claims against one another in a lawsuit over the patent for MS drug Tecfidera. In an October 14 order by Federal Court Justice Helen Rofe, Biogen’s infringement claims and Pharmacor’s cross-claims seeking to invalidate the lucrative patent were discontinued by consent without…
Boutique firm Marquette IP has reached a settlement with a former trade mark attorney who claimed she was sacked for making complaints of bullying by a supervisor.
Melbourne restaurant College Dropout Burgers has been hit with a lawsuit by Kanye West for allegedly using the controversial rapper’s name and likeness without permission.
Education superannuation fund NGS Super has filed a trade mark lawsuit against Australian blockchain mining company NGS Crypto, claiming it failed to comply with a promise to rebrand and continues to profit at the fund’s expense.
French drug giant Sanofi has appealed a decision giving American biopharmaceutical company Amgen the go-ahead for its patents for a cholesterol-lowering antibody that could be used to treat heart disease, diabetes, stroke and Alzheimer’s.